HOME >> MEDICINE >> NEWS
New drug regimen shows clear benefit for treating advanced colorectal cancer

Initial results from a large, randomized clinical trial for patients with advanced colorectal cancer show that those who received a regimen containing the investigational drug oxaliplatin lived months longer than those who received a standard therapy. Patients on the oxaliplatin regimen, known as FOLFOX4, also had a longer time before their tumors progressed, a better response rate, and fewer severe side effects.

Sponsored by the National Cancer Institute (NCI), the trial has been conducted by a network of researchers led by the North Central Cancer Treatment Group (NCCTG).* Study chair Richard Goldberg, M.D., of the Mayo Clinic Cancer Center, Rochester, Minn., presented the new data today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.

"This trial has given us important new information about the treatment of advanced colorectal cancer," said Richard Kaplan, M.D., chief of NCI's Clinical Investigations Branch, who coordinates colorectal cancer treatment trials sponsored by NCI. "The patient benefit seen with the FOLFOX4 regimen is encouraging; FOLFOX4 is a promising new option in our armamentarium of treatments for colorectal cancer."

The trial, known as N9741, compared three drug regimens: 1) a standard (control) treatment, known as IFL (irinotecan/5-fluorouracil/leucovorin) or the "Saltz regimen," 2) the experimental regimen FOLFOX4 (5-fluorouracil/leucovorin/oxaliplatin) and 3) another experimental regimen combining oxaliplatin and irinotecan.

In a planned interim analysis of the data, the researchers found that outcomes for patients receiving FOLFOX4 were significantly better than for those on the control arm, IFL. Patients on the FOLFOX4 arm lived about four months longer than those on the IFL arm (median 18.6 months vs. 14.1 months). They also had a significantly better time to tumor progression (median 8.8 months vs. 6.9 months) and higher response rates (38 percent vs. 29 perc
'"/>

Contact: NCI Press Office
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
18-May-2002


Page: 1 2 3

Related medicine news :

1. Study examines three-day antibiotic regimens for treating bladder infection in women
2. Study assessing once daily Abacavir (ABC) in a once daily ART regimen
3. Study compares three weekly regimens of chemotherapy for lung cancer
4. Vitamin E fails to join heart-health regimen
5. Newer lung cancer treatments extend survival longer than traditional regimens
6. Emory University will conduct clinical trial of anthrax vaccine regimen
7. 7-day-on, 7-day-off regimen could reduce cost, toxicities of HIV therapy
8. Drug regimen adherence key in keeping babies virus-free, study suggests
9. HIV patients more likely to accept a drug regimen if they trust in the physician, Yale researchers find
10. Are people with HIV sticking to their medication treatment regimens? New method measures patient adherence
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT , Hespiro™ is ... with respiratory conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. ... exhaled gas and scrubs it free of carbon dioxide in a completely closed ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True North Classical ... Indoor Air Protection System that is the first system designed and proven to catch ... the filtration system on September 8th. , The IVP Air S1 model is ...
(Date:8/27/2020)... ... 2020 , ... Walk-in Dermatology’s SK-IN Medical Aesthetics Center announced ... York location. , Loren received her New York esthetic license in 2009 ... peels, microdermabrasion, Hydrafacial MD, dermaplaning, facial lymphatic, and various laser procedures. Loren is ...
(Date:8/26/2020)... ... 2020 , ... Smile Brands Inc. CEO, Steven C. Bilt, ... a session entitled, “A CEO Guide for Delivering and Measuring Inclusion Success”. The ... together the world’s leading diversity and inclusion executives, HR consultants, and D&I activists ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... Hero Life Sciences announced today that ... 3 ply surgical disposable face masks and N95 respirators in its manufacturing plant located ... challenge that most Americans are facing in trying to find quality disposable face masks ...
(Date:8/26/2020)... ... 26, 2020 , ... NucleusHealth, LLC, a provider of market ... and Chief Executive Officer effective immediately. Dr. Vishal Verma, the previous CEO, will ... , Mr. Hooton, a seasoned business executive, joined the company in February ...
(Date:8/26/2020)... SAN DIEGO (PRWEB) , ... August 25, 2020 ... ... opening of its brand new Stem Cell Treatment Center to give ... stress free environment. With this announcement, ProgenCell establishes its leadership in the field ...
Breaking Medicine Technology:
Cached News: